What the first human BPC-157 safety study actually found

The first published study to give people intravenous BPC-157 and check their blood afterwards involved two adults at a private clinic in Florida. Each received 10 mg on one day and 20 mg the next; neither reported side effects, and their heart, liver, kidney, thyroid and blood-sugar tests didn't change [1]. The authors conclude the pilot “showed the safety of BPC-157 in humans”. Two people over three days can't show that.

Why this study matters

BPC-157 is a short synthetic peptide that has been used, in the authors' words, to treat partial muscle or tendon tears for years, yet the paper itself notes that few human studies have been published and none on intravenous use [1]. Most of the research on it has been in animals and cells, so any paper with “humans” in the title gets passed around quickly.

Lee and Burgess published this one in Alternative Therapies in Health and Medicine in 2025 [1]. It's a real first. The question is what kind of first.

What they did

The study, approved by an institutional review board, ran at a private clinic in Florida [1]. Blood tests and vital signs were taken before and after each infusion. On day 1, each participant received 10 mg of BPC-157 in 250 mL of normal saline over an hour. On day 2, after fasting blood work, they got 20 mg the same way. On day 3, fasting bloods and vital signs were repeated. At each visit the participants were asked about side effects [1].

Both participants had already received intravenous BPC-157 before the study [1].

What they found

According to the abstract, the infusions had no measurable effect on the tested markers of heart, liver, kidney and thyroid function or on blood glucose, and neither participant reported any side effects [1]. The abstract doesn't list the individual tests or give the values, and we couldn't access the full text to check them.

That's the whole result. There was no efficacy question here: the study didn't look at healing, pain or any condition.

What a two-person pilot can and can't tell you

What it can tell you. In these two people, on these two days, 10 mg and then 20 mg of this particular BPC-157 preparation given into a vein didn't cause an immediate reaction or a change in standard blood tests. For researchers planning a proper trial, that's a small piece of information about the doses and route.

What it can't tell you. Almost everything else. Here's why:

• Two people can't rule out anything uncommon. If a side effect never appears in two people, statistics can't exclude it being common. Using a standard statistical bound, by our own arithmetic, the true rate could still be as high as roughly three in four. Real safety studies enrol hundreds or thousands of people to catch reactions that happen in one in a hundred or one in a thousand.
• Both had used it before. Recruiting people who had already had intravenous BPC-157 means recruiting people who presumably tolerated it. Anyone who'd reacted badly the first time would be less likely to sign up for more.
• Three days is not long-term. The study can't speak to anything that develops over weeks or months, including immune reactions or effects on tissue growth.
• No comparison group and no blinding. With no placebo, there's no way to separate a drug effect from normal day-to-day variation, though with no changes found this matters less than usual.
• Details the abstract doesn't give. It doesn't describe where the BPC-157 came from, how its purity was checked, or whether blood levels of the peptide were measured [1]. It doesn't include a funding or conflict-of-interest statement either.

The conclusion that the study “showed the safety of BPC-157 in humans” goes well beyond the data. The authors do add, in the same abstract, that future studies are needed to confirm the safety of intravenous BPC-157 [1]. That second sentence is the accurate one.

Where it sits in the human evidence

The same first author has published two other small, uncontrolled BPC-157 reports in the same journal. One was a retrospective phone survey of 16 patients who'd had knee injections of BPC-157, alone or with thymosin beta-4; 14 reported relief, but no standard measurement tools were used [2]. The other gave 12 women with interstitial cystitis a single set of bladder-wall injections totalling 10 mg; all reported improvement and no adverse events were recorded [3]. Neither had a control group.

Put together, that's 30 people across three uncontrolled reports, all with the same first author. No randomised, placebo-controlled trial of BPC-157 in people has been published in the sources we checked.

Regulators have noticed the gap. The US Food and Drug Administration's page on bulk drug substances that may present significant safety risks in compounding lists BPC-157 among substances whose nominations were withdrawn. For BPC-157, it says it has identified no, or only limited, safety information for the proposed routes of administration, and flags possible immunogenicity and impurity concerns [4].

What it means in practice

This paper is best read as a feasibility note, not a safety verdict. It adds two data points to a very thin human record. It doesn't show that intravenous BPC-157 is safe, only that two experienced users didn't have a problem over three days. Anyone citing it as “BPC-157 is proven safe in humans” is leaning on a study that can't carry that weight.

What is still open

• Whether BPC-157 causes uncommon or delayed side effects in people, by any route.
• What happens to blood levels of the peptide after injection or infusion, and how long it lasts.
• How much products sold as BPC-157 vary in purity and content.
• Whether it does anything useful in people at all; no controlled human efficacy trial has been published.

What this means

Our position is that this pilot earns BPC-157 a place on the shortlist for a properly powered safety study, and nothing more. It is the first paper to put intravenous BPC-157 into people and check the blood afterwards, and it clears the immediate hurdle: two adults received 10 mg and then 20 mg with no side effects reported and no change in the markers tested [1]. Read as a feasibility note, that is a real if very small step — the kind a first-in-human study is meant to take. Read as proof, it is not that, and we would not tell anyone to rely on it.

Where we part company with the authors is the word "safety". Two people free of side effects over three days cannot rule out a reaction that happens in one in a hundred or one in a thousand, and both participants had already tolerated intravenous BPC-157 before they enrolled [1]. A study that recruits people who have already had the drug can only tell you what happened to the people who did not react. We hold the paper to what it measured: a dose and a route that appeared tolerable in two experienced users, on two days.

For a reader weighing BPC-157 today, our direction is specific rather than general. The open question is not "does BPC-157 work" — that is unanswered for every route in people — but what is actually in the vial in front of you. The FDA's compounding page flags BPC-157 for limited safety information on the proposed routes of administration, alongside possible immunogenicity and impurity concerns [4]. That is why purity, sterility, endotoxin and heavy-metal testing are worth demanding before the peptide's human record matters at all. We would rather a reader ask for those certificates than read a two-person pilot as a green light — and, just as firmly, we would not read it as a verdict against the compound. A thin basis is a thin basis; it is not a failure.

What readers report

First-hand accounts, shared with permission. They are self-reported, not evidence, and sit alongside the research above rather than in place of it.

Educational content only — not medical advice. Many peptides discussed on HPR are not approved for human use. Talk to a qualified clinician before making any decision about your health.